Excellent! McCormick/Unilever deal is huge news. Now I have enough material for a strong analyst note. Let me write the article focusing on:
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Excellent! McCormick/Unilever deal is huge news. Now I have enough material for a strong analyst note. Let me write the article focusing on:
- Aptiv - split analyst calls (Morgan Stanley raise, Barclays cut)
- Lamb Weston - Deutsche Bank cut ahead of earnings
- Starbucks - Citizens JMP initiated with underperform
- McCormick - Unilever deal context
Analysts Split on Auto Suppliers
APTV Aptiv drew conflicting calls yesterday. Morgan Stanley raised its target to $87 from $81 while keeping equal weight. Barclays slashed to $77 from $85 maintaining overweight. The $16B auto supplier faces diverging views on its electrification strategy.
LW Lamb Weston absorbed a Deutsche Bank downgrade to hold. The target fell to $40 from $47 ahead of Q3 earnings today. The $5.5B frozen potato maker battled weak restaurant demand as consumers cut dining budgets.
SBUX Starbucks earned a rare underperform initiation from Citizens JMP. The new coverage arrived as the coffee giant announced 69 layoffs and five Washington store closures. The $97B chain struggled with slowing traffic and labor costs.
MKC McCormick dominated headlines with its $60B Unilever foods merger announcement. The spice maker beat Q1 estimates posting 66 cents EPS versus 60 cents expected. Sales hit $1.87B topping $1.79B forecasts. The deal combines Knorr and Hellmann's with McCormick brands creating a global flavor giant.
Auto sector calls remained fractured as analysts debated EV transition timing. Food and restaurant names faced mounting pressure.
How this article was generated
- Generated
- 31 Mar 2026, 12:23
- Prompt version
- migrated
- Data sources
- Analyst consensusAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.